Loading
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Previous close
$2.17
−$0.03 · -1.36%
Regular session · ET · Market data may be delayed.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Day range
Current $2.17
52-week range
Current $2.17
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Sentiment
45
Mixed
Risk
69
High Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Day range
Current $2.17
52-week range
Current $2.17
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 46K USD | — | — | — | 519K USD |
| Gross profit | −46K USD | — | — | — | −519K USD |
| Research and development | 15.23M USD | 14.48M USD | 15.86M USD | 8.35M USD | 18.9M USD |
| Selling, general, and administrative | 7.89M USD | 9.73M USD | 22.22M USD | 5.84M USD | 17.04M USD |
| Operating expenses | 23.12M USD | 24.2M USD | 38.08M USD | 14.19M USD | 35.43M USD |
| Interest income | 713K USD | — | — | — | 126K USD |
| Interest expense | 1.42M USD | — | 110K USD | 132K USD | 126K USD |
| Depreciation and amortization | 46K USD | 58K USD | 58K USD | 52K USD | 519K USD |
| Operating income | −23.12M USD | −24.2M USD | −38.08M USD | −14.19M USD | −35.95M USD |
| Net income | −29.56M USD | −13.7M USD | −34.36M USD | −7.82M USD | −35.82M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$266
12158.06% upsidePrice history unavailable
High $392Average $266Low $14.00Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
